Who are Diamox's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sodium Nitrite, Banzel, Tri-Luma, Azopt, Trusopt, Fludara.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acetazolamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Diamox — Competitive Intelligence Brief

Diamox (ACETAZOLAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic Anhydrase Inhibitor [EPC]. Area: Immunology.

marketed Carbonic Anhydrase Inhibitor [EPC] Carbonic anhydrase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Diamox (ACETAZOLAMIDE) — Teva.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diamox TARGET	ACETAZOLAMIDE	Teva	marketed	Carbonic Anhydrase Inhibitor [EPC]	Carbonic anhydrase	1953-01-01
Sodium Nitrite	SODIUM NITRITE	Hope Pharms	marketed	sodium nitrite	Carbonic anhydrase 1	2011-01-01
Banzel	RUFINAMIDE	Eisai	marketed	rufinamide	Carbonic anhydrase 5A, mitochondrial	2008-01-01
Tri-Luma	HYDROQUINONE	Galderma Labs Lp	marketed	Melanin Synthesis Inhibitor [EPC]	Carbonic anhydrase 2	2002-01-01
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
Trusopt	DORZOLAMIDE	Merck & Co.	marketed	Carbonic Anhydrase Inhibitor	Carbonic anhydrase 2	1994-01-01
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	marketed	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic Anhydrase Inhibitor [EPC] class)

· 1 drug in this class
Novartis · 1 drug in this class
Teva · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diamox — Competitive Intelligence Brief. https://druglandscape.com/ci/acetazolamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab